New cocktail targets advanced colon cancer
NCT ID NCT00556413
First seen Feb 05, 2026 · Last updated May 24, 2026 · Updated 16 times
Summary
This study tested whether adding cetuximab (a targeted antibody) to a strong chemotherapy cocktail (FOLFIRINOX) could shrink tumors better in people with metastatic colorectal cancer that had spread and could not be removed by surgery. 42 patients received the combination as their first treatment. The goal was to see how many had a complete response and to track side effects and survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Centre Regional de Lutte Contre le Cancer - Centre Val d'Aurelle
Montpellier, 34298, France
Conditions
Explore the condition pages connected to this study.